Archivio istituzionale della ricerca dell'Università degli Studi di Palermo

PASSIGLIA, Francesco
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.399
EU - Europa 2.143
AS - Asia 2.037
SA - Sud America 311
AF - Africa 39
OC - Oceania 6
Continente sconosciuto - Info sul continente non disponibili 2
Totale 10.937
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.321
SG - Singapore 803
RU - Federazione Russa 588
CN - Cina 532
IT - Italia 510
BR - Brasile 241
DE - Germania 226
FI - Finlandia 188
VN - Vietnam 187
HK - Hong Kong 180
GB - Regno Unito 139
PL - Polonia 119
FR - Francia 87
IE - Irlanda 87
JP - Giappone 67
KR - Corea 54
SE - Svezia 48
IN - India 47
CA - Canada 39
BD - Bangladesh 29
TR - Turchia 28
IQ - Iraq 25
UA - Ucraina 23
AR - Argentina 22
RO - Romania 22
ES - Italia 19
NL - Olanda 19
BE - Belgio 17
MX - Messico 16
UZ - Uzbekistan 15
EC - Ecuador 12
VE - Venezuela 12
MA - Marocco 10
CH - Svizzera 9
IR - Iran 9
AT - Austria 8
CO - Colombia 8
ID - Indonesia 8
PK - Pakistan 8
PY - Paraguay 8
ZA - Sudafrica 7
KE - Kenya 6
CI - Costa d'Avorio 5
CZ - Repubblica Ceca 5
LB - Libano 5
PT - Portogallo 5
SA - Arabia Saudita 5
AU - Australia 4
DK - Danimarca 4
JM - Giamaica 4
MY - Malesia 4
PH - Filippine 4
UY - Uruguay 4
BG - Bulgaria 3
CL - Cile 3
DZ - Algeria 3
EG - Egitto 3
GT - Guatemala 3
IL - Israele 3
NI - Nicaragua 3
NP - Nepal 3
TW - Taiwan 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AE - Emirati Arabi Uniti 2
AL - Albania 2
AZ - Azerbaigian 2
GR - Grecia 2
HN - Honduras 2
HR - Croazia 2
KG - Kirghizistan 2
MD - Moldavia 2
MO - Macao, regione amministrativa speciale della Cina 2
NZ - Nuova Zelanda 2
PA - Panama 2
SV - El Salvador 2
TT - Trinidad e Tobago 2
AM - Armenia 1
BM - Bermuda 1
BO - Bolivia 1
BW - Botswana 1
BY - Bielorussia 1
CU - Cuba 1
DO - Repubblica Dominicana 1
EE - Estonia 1
ET - Etiopia 1
GD - Grenada 1
GE - Georgia 1
GH - Ghana 1
GP - Guadalupe 1
HU - Ungheria 1
JO - Giordania 1
KW - Kuwait 1
KZ - Kazakistan 1
LT - Lituania 1
LU - Lussemburgo 1
LV - Lettonia 1
MC - Monaco 1
MN - Mongolia 1
NA - Namibia 1
NG - Nigeria 1
Totale 10.931
Salva come PNG Salva come JPEG
Città #
Fairfield 1.017
Ashburn 681
Singapore 535
Woodbridge 462
Seattle 432
Cambridge 353
Wilmington 351
Houston 347
Chandler 336
San Jose 247
Ann Arbor 195
Hong Kong 173
Palermo 117
Moscow 112
Zgierz 99
Beijing 97
Council Bluffs 92
Helsinki 88
Dublin 82
Medford 82
Santa Clara 76
Los Angeles 74
Nanjing 73
Altamura 69
New York 59
Ho Chi Minh City 58
Des Moines 57
Boardman 55
Tokyo 55
Lauterbourg 53
Princeton 53
Lawrence 50
San Diego 49
The Dalles 46
Hanoi 40
Dallas 38
Saint Petersburg 35
Dearborn 33
Chicago 32
Frankfurt am Main 31
Phoenix 31
Ludwigshafen am Rhein 30
Hefei 28
London 28
Seoul 28
Kitzingen 25
Panama City 23
Buffalo 22
Tianjin 21
Rome 20
Shenyang 20
Atlanta 18
Jinan 18
Hebei 17
Redwood City 17
Brussels 16
Milan 15
São Paulo 15
Warsaw 15
Baghdad 14
Changsha 14
Bremen 13
Da Nang 13
Izmir 13
Jiaxing 13
Nanchang 13
Nuremberg 13
Orem 13
Tulsa 13
Rio de Janeiro 12
Amsterdam 11
Kumar 11
Stockholm 10
Belo Horizonte 9
Denver 9
Manchester 9
Ningbo 9
Seongnam 9
Tashkent 9
Zhengzhou 9
Brooklyn 8
Columbus 8
San Paolo di Civitate 8
Surrey 8
Boydton 7
Casablanca 7
Haiphong 7
Pune 7
Quito 7
Shanghai 7
Buenos Aires 6
Falls Church 6
Joinville 6
Mexico City 6
Munich 6
Abidjan 5
Ankara 5
Cagliari 5
Campinas 5
Edinburgh 5
Totale 7.709
Salva come PNG Salva come JPEG
Nome #
PD-L1 expression as predictive biomarker in patients with NSCLC: A pooled analysis 347
EGFR inhibition in NSCLC: New findings…. and opened questions? 342
Stabilizing versus destabilizing the microtubules: A double-edge sword for an effective cancer treatment option? 315
Analysis of Germline Gene Copy Number Variants of Patients with Sporadic Pancreatic Adenocarcinoma Reveals Specific Variations 311
"Back to a false normality": New intriguing mechanisms of resistance to PARP inhibitors 305
Entrectinib: A potent new TRK, ROS1, and ALK inhibitor 284
Monitoring blood biomarkers to predict nivolumab effectiveness in NSCLC patients 280
Are erlotinib and gefitinib interchangeable, opposite or complementary for non-small cell lung cancer treatment? Biological, pharmacological and clinical aspects 275
Extracellular Vesicles As miRNA Nano-Shuttles: Dual Role in Tumor Progression 275
Metastatic site location influences the diagnostic accuracy of ctDNA EGFR- mutation testing in NSCLC patients: a pooled analysis 261
New findings on primary and acquired resistance to anti-EGFR therapy in metastatic colorectal cancer: Do all roads lead to RAS? 258
Nintedanib in NSCLC: Evidence to date and place in therapy 258
Cardiotoxicity mechanisms of the combination of BRAF-inhibitors and MEK-inhibitors 256
What can platinum offer yet in the treatment of PS2 NSCLC patients? A systematic review and meta-analysis 250
Cancer and the microbiome: Potential applications as new tumor biomarker 244
Immunotherapy: is a minor god yet in the pantheon of treatments for lung cancer? 238
Immuno-targeted combinations in oncogene-addicted non-small cell lung cancer 232
The role of targeted therapy for gastrointestinal tumors 230
Detection of RAS mutations in circulating tumor DNA: a new weapon in an old war against colorectal cancer. A systematic review of literature and meta-analysis 228
Multisciplinary management of patients with liver metastasis from colorectal cancer 224
Potential Role of ANGPTL4 in the Cross Talk between Metabolism and Cancer through PPAR Signaling Pathway 221
The comparison of outcomes from tyrosine kinase inhibitor monotherapy in second- or third-line for advanced non-small-cell lung cancer patients with wild-type or unknown EGFR status 221
Circulating programmed death ligand-1 (cPD-L1) in non-smallcell lung cancer (NSCLC) 214
Prognostic clinical factors in patients affected by non-small-cell lung cancer receiving Nivolumab 213
Novel therapeutic strategies for patients with NSCLC that do not respond to treatment with EGFR inhibitors 205
The diagnostic accuracy of circulating tumor DNA for the detection of EGFR-T790M mutation in NSCLC: a systematic review and meta-analysis 205
Can KRAS and BRAF mutations limit the benefit of liver resection in metastatic colorectal cancer patients? A systematic review and meta-analysis 204
Monoclonal antibodies for the treatment of non-haematological tumours: Update of an expanding scenario 202
Looking for the best immune-checkpoint inhibitor in pre-treated NSCLC patients: An indirect comparison between nivolumab, pembrolizumab and atezolizumab 202
Liquid biopsies in lung cancer: The new ambrosia of researchers 200
Improvement in lung cancer outcomes with targeted therapies: An update for family physicians 195
Liquid Biopsy in Non-Small Cell Lung Cancer (NSCLC) 192
Management of Toxicity Induced by Anti-EGFR Therapy in Metastatic Colorectal Cancer 186
Anti-angiogenic drugs for second-line treatment of NSCLC patients: Just new pawns on the chessboard? 179
The potential of neurotrophic tyrosine kinase (NTRK) inhibitors for treating lung cancer 176
The role of microRNAs in driving EGFR-TKI resistance in NSCLC cell lines 172
Circulating tumor DNA (ctDNA) as predictive biomarker in NSCLC patients treated with Nivolumab 169
ALK and crizotinib: After the honeymoon...what else? Resistance mechanisms and new therapies to overcome it 167
The resistance related to targeted therapy in malignant pleural mesothelioma: Why has not the target been hit yet? 166
Immune-checkpoint inhibitors in non-small cell lung cancer: A tool to improve patients’ selection 165
Looking for a new panacea in ALK-rearranged NSCLC: may be Ceritinib? 162
Impact of phospho-Akt expression on the clinical outcome and activity of gemcitabine and Akt inhibitors in pancreatic ductal adenocarcinoma 162
Prognostic and predictive biomarkers for targeted therapy in NSCLC: For whom the bell tolls? 156
The role of cMET in non-small cell lung cancer resistant to EGFR-Inhibitors: Did we really find the target? 152
Second-Line Treatment of Non-Small Cell Lung Cancer: Clinical, Pathological, and Molecular Aspects of Nintedanib 150
Immune-Biomarkers in Advanced Non-Small Cell Lung Cancer 149
Immunotherapy in non-small-cell lung cancer: a bridge between research and clinical practice. 145
Upfront radiation versus EGFR-TKI: Which is the best approach for EGFR-mutated NSCLC patients with brain metastasis? 143
Corrigendum to "Liquid biopsies in lung cancer: The new ambrosia of researchers" [Biochem. Biophys. Act. 1846(2014) 539-546] 143
The effects of enzalutamide and abiraterone on skeletal related events and bone radiological progression free survival in castration resistant prostate cancer patients: An indirect comparison of randomized controlled trials 141
Ramucirumab and its use in gastric cancer treatment 140
The challenge of the Molecular Tumor Board empowerment in clinical oncology practice: A Position Paper on behalf of the AIOM- SIAPEC/IAP-SIBioC-SIC-SIF-SIGU-SIRM Italian Scientific Societies 116
The prognostic role of KRAS and BRAF in patients undergoing surgical resection of colorectal cancer liver metastasis: a systematic review and meta-analysis 110
Monoclonal antibodies for the treatment of non-hematological tumors: a safety review 109
Publisher Correction: The diagnostic accuracy of circulating tumor DNA for the detection of EGFR-T790M mutation in NSCLC: a systematic review and meta-analysis 49
Totale 11.294
Salva come PNG Salva come JPEG
Categoria #
all - tutte 38.165
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 38.165
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022723 34 137 55 24 33 36 31 61 64 81 56 111
2022/2023967 98 206 23 120 100 137 48 70 85 10 47 23
2023/2024366 13 55 32 22 18 63 46 25 5 11 7 69
2024/20251.104 17 120 106 80 32 46 86 107 50 107 128 225
2025/20263.422 293 112 195 270 376 442 506 430 263 247 112 176
2026/2027120 120 0 0 0 0 0 0 0 0 0 0 0
Totale 11.294